Bioscience Company Achieves Promising Macroglobulinemia Treatment Results

Breakthrough in Waldenstrom's Macroglobulinemia Treatment: Cellectar Biosciences Achieves Primary Endpoint in Pivotal Clinical Study.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant development for patients with Waldenstrom's Macroglobulinemia, Cellectar Biosciences has announced positive topline data from its pivotal clinical study of Iopofosine I 131, a novel therapy th…